Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSH | P09668 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806473 | 0.74 | CYP1A2 (0.39) | SMN1; SMN2MEN1KMT2ALMNACYP3A4 | |
| SCHEMBL31120928 | 0.74 | CYP1A2 (0.39) | SMN1; SMN2MEN1KMT2ALMNACYP3A4 | |
| SCHEMBL28754472 | 0.74 | TSHR (0.37) | SMN1; SMN2MEN1KMT2ALMNAHSD17B10 | |
| SCHEMBL31484441 | 0.72 | LMNA (0.39) | SMN1; SMN2MEN1KMT2ALMNAHSD17B10 | |
| SCHEMBL2262199 | 0.72 | LMNA (0.37) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL2260698 | 0.72 | LMNA (0.37) | MEN1KMT2ALMNATSHRALDH1A1 | |
| SCHEMBL27865031 | 0.71 | LMNA (0.41) | SMN1; SMN2LMNAHSD17B10TSHRCYP3A4 | |
| SCHEMBL1055128 | 0.71 | TDP1 (0.48) | MEN1KMT2ALMNAHSD17B10TSHR | |
| SCHEMBL8159648 | 0.71 | VCAM1 (0.43) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL29390318 | 0.71 | TDP1 (0.48) | MEN1KMT2ALMNAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| CN-1312154-C | Purine derivatives as kinase inhibitors | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| CN-1639152-A | Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1639165-A | Purine derivatives as kinase inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
| EP-1487822-A2 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1483265-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076442-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076398-A2 | PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | SMN1; SMN2 4465/4885MEN1 3239/4885KMT2A 1752/4885 |
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | SMN1; SMN2 4465/4885MEN1 3239/4885KMT2A 1752/4885 |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | SMN1; SMN2 4465/4885MEN1 3239/4885KMT2A 1752/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | SMN1; SMN2 4465/4885MEN1 3239/4885KMT2A 1752/4885 |
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | SMN1; SMN2 4318/4885MEN1 1394/4885KMT2A 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.